– Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program  Aspacytarabine (BST-236)   in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) – Combined Company Will be Well-Funded with Cash Position of approx.$50

ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA ® Expansion of off-the-shelf ADXS-HOT program with planned Phase 1 study in early prostate cancer with

Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab Translational data support potential of ADXS-503 to restore and/or enhance sensitivity to checkpoint inhibitors PRINCETON, N.J., May 19,

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) --  Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination

Non-dilutive capital will support advancement of ADXS-HOT neoantigen program PRINCETON, N.J., April 26, 2021 (GLOBE NEWSWIRE) --  Advaxis, Inc.  (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that

Non-dilutive capital to support advancement of ADXS-HOT neoantigen program PRINCETON, N.J., April 26, 2021 (GLOBE NEWSWIRE) --  Advaxis, Inc.  (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the

PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) --  Advaxis, Inc. (Nasdaq: ADXS)  (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into definitive agreements with two

Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade Assay enables determination of PD-1 expression independent of PD-1 receptor status, accounting for both free and drug-bound PD-1 Results

Initiation of Phase 1 study in biochemically recurrent prostate cancer anticipated in Q2 PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today

PRINCETON, N.J., March 23, 2021 (GLOBE NEWSWIRE) --  Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will